ML Strategies Co-Authors Report on Effect of Alternative Payment Models on Personalized Medicine
Hosting Panel Discussion in Conjunction with Release of White Paper
ML Strategies, the government relations and strategic consulting affiliate of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., is hosting an event with leading government and industry experts around a white paper it co-authored with the Personalized Medicine Coalition (PMC) on how Alternative Payment Models (APMs) could affect paying for personalized medicine.
The report will be released during a panel discussion and reception on April 23rd in ML Strategies’ Washington, D.C. office.
The white paper, which was developed by ML Strategies in partnership with PMC, a nonprofit education and advocacy organization, explores the potential positive and negative consequences that APMs might have on personalized medicine, with a particular focus on how Accountable Care Organizations (ACOs), bundled payments, medical homes and clinical pathways might impact the field. In its conclusion, the paper encourages policymakers to engage stakeholders as they consider large-scale payment reforms, to ensure that patient access to personalized medicine products and services is not disrupted.
The panel discussion will be moderated by Amy M. Miller, Ph.D., Executive Vice President of PMC. Panelists include Andy Shin, Director of Health Care Policy and Life Sciences for ML Strategies, Von Nguyen, Senior Advisor, Innovation Center, Centers for Medicare & Medicaid Services (CMS) and Scott Jauch, Director of Policy for AstraZeneca.